SAM
REGN icon

Solaris Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Solaris Asset Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-348
Closed -$120K – 49
2018
Q1 		$120K Buy
348
+223
+178% +$77.6K 0.79% 29
2017
Q4 		$47K Buy
+125
New +$50.6K 0.03% 169
2016
Q1 		– Sell
-3
Closed -$2K – 200
2015
Q4 		$2K Hold
3
– – ﹤0.01% 179
2015
Q3 		$1K Buy
+3
New +$1.61K ﹤0.01% 171

Other funds holding REGN

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Solaris Asset Management's REGN Position: Q2 2018 in Review

Solaris Asset Management sold out of Regeneron Pharmaceuticals (REGN) in Q2 2018, closing a stake of 348 shares — an estimated $120K sold.

Solaris Asset Management first reported a position in REGN in Q3 2015 and held it in 4 quarters. The position peaked at $120K in Q1 2018. 624 funds tracked by Wall St. Rank hold REGN as of Q2 2018.

  • Solaris Asset Management reported no remaining Regeneron Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Solaris Asset Management sold 348 Regeneron Pharmaceuticals shares in Q2 2018, an estimated $120K.
  • Solaris Asset Management first reported a position in Regeneron Pharmaceuticals in Q3 2015 and held it in 4 quarters.
  • Solaris Asset Management's Regeneron Pharmaceuticals position peaked at $120K in Q1 2018.
  • 624 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2018.

Based on Solaris Asset Management's 13F filing for Q2 2018, filed 26 Jul 2018.